Exelixis, Inc. (EXEL)
56.53
-0.90
(-1.57%)
USD |
NASDAQ |
Sep 11, 14:42
Exelixis Gross Profit (TTM) : 2.350B for June 30, 2026
Gross Profit (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.350B |
| March 31, 2026 | 2.291B |
| December 31, 2025 | 2.236B |
| September 30, 2025 | 2.211B |
| June 30, 2025 | 2.154B |
| March 31, 2025 | 2.225B |
| December 31, 2024 | 2.092B |
| September 30, 2024 | 2.004B |
| June 30, 2024 | 1.935B |
| March 31, 2024 | 1.767B |
| December 31, 2023 | 1.758B |
| September 30, 2023 | 1.708B |
| June 30, 2023 | 1.651B |
| March 31, 2023 | 1.605B |
| December 31, 2022 | 1.553B |
| September 30, 2022 | 1.583B |
| June 30, 2022 | 1.503B |
| March 31, 2022 | 1.468B |
| December 31, 2021 | 1.382B |
| September 30, 2021 | 1.205B |
| June 30, 2021 | 1.111B |
| March 31, 2021 | 990.67M |
| December 31, 2020 | 951.27M |
| September 30, 2020 | 920.04M |
| June 30, 2020 | 961.84M |
| Date | Value |
|---|---|
| March 31, 2020 | 944.32M |
| December 31, 2019 | 934.68M |
| September 30, 2019 | 926.14M |
| June 30, 2019 | 880.01M |
| March 31, 2019 | 827.38M |
| December 31, 2018 | 826.10M |
| September 30, 2018 | 720.74M |
| June 30, 2018 | 650.65M |
| March 31, 2018 | 566.53M |
| December 31, 2017 | 437.51M |
| September 30, 2017 | 397.36M |
| June 30, 2017 | 309.15M |
| March 31, 2017 | 247.84M |
| December 31, 2016 | 184.90M |
| September 30, 2016 | 118.09M |
| June 30, 2016 | 66.40M |
| March 31, 2016 | 38.63M |
| December 31, 2015 | 32.21M |
| September 30, 2015 | 29.97M |
| June 30, 2015 | 25.71M |
| March 31, 2015 | 24.28M |
| December 31, 2014 | 20.05M |
| September 30, 2014 | 16.70M |
| June 30, 2014 | 17.33M |
| March 31, 2014 | 22.62M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 3.827B |
| BioMarin Pharmaceutical, Inc. | 2.556B |
| Cytokinetics, Inc. | 46.98M |
| Emergent BioSolutions, Inc. | 363.30M |
| Gilead Sciences, Inc. | 24.33B |